LUPIN2024-10-012024-12-31 LUPIN2024-10-012024-12-31 LUPIN2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member LUPIN2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member LUPIN2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member LUPIN2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member LUPIN2024-12-31 LUPIN2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue01Member LUPIN2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue02Member LUPIN2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue01Member LUPIN2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue02Member LUPIN2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults01Member LUPIN2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults02Member LUPIN2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults01Member LUPIN2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults02Member LUPIN2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets01Member LUPIN2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets02Member LUPIN2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member LUPIN2024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member LUPIN2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member LUPIN2024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member LUPIN2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LUPIN2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LUPIN2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member LUPIN2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500257 LUPIN NOTLISTED Lupin Limited Equity 2024-04-01 2025-03-31 2025-02-11 2025-01-27 INR Millions Third quarter 21:00:00 23:59:00 2025-02-11 2025-02-11 Not applicable Multi segment 2024-10-01 2024-12-31 Unaudited Consolidated 57677100000.00 537100000.00 58214200000.00 10840900000.00 7663900000.00 -1289300000.00 9843900000.00 668900000.00 2714500000.00 17058700000.00 47501500000.00 10712700000.00 0.00 10712700000.00 2691000000.00 -566900000.00 2124100000.00 0.00 8588600000.00 0.00 0.00 0.00 0.00 8588600000.00 -1195300000.00 7393300000.00 8551600000.00 37000000.00 7365900000.00 27400000.00 912500000.00 2 18.75 18.69 0.00 0.00 18.75 18.69 0.00 0.00 0.00 Please note that the Board meeting commenced on 11.02.2025 at 09:00 p.m. (IST) and concluded on 12.02.2025, at 12:10 a.m. (IST). Due to technical issue faced while uploading the XBRL file on NSE Neaps Portal and as suggested by NSE Technical Team, we have mentioned Board Meeting concluded on 11.02.2025, at 23:59 hrs (IST). We request you to consider Board Meeting conclusion date and time as 12.02.2025, at 00:10 hrs (IST). Notes to Financial Results 1. The above Consolidated Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 11.02.2025. The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to Regulation 33 of the SEBI LODR Regulations, 2015. 2. The Consolidated Financial Results include the financial results of the subsidiaries, Lupin Pharmaceuticals, Inc. - U.S.A., Lupin Australia Pty Limited - Australia, Nanomi B.V. Netherlands, Pharma Dynamics (Proprietary) Limited - South Africa, Hormosan Pharma GmbH - Germany, Multicare Pharmaceuticals Philippines Inc. - Philippines, Lupin Atlantis Holdings SA - Switzerland, Lupin Healthcare (UK) Limited - U.K., Lupin Pharma Canada Limited - Canada, Generic Health Pty Limited - Australia, Bellwether Pharma Pty Limited - Australia (upto June 11, 2023), Lupin Mexico S.A. de C.V. - Mexico, Lupin Philippines Inc. - Philippines, Lupin Diagnostics Limited - India, Generic Health SDN. BHD. - Malaysia, Lupin Inc. - U.S.A., Laboratorios Grin S.A. de C.V. - Mexico, Medquimica Industria Farmaceutica LTDA - Brazil, Novel Laboratories, Inc.- U.S.A., Lupin Research Inc. - U.S.A., Lupin Management Inc. - U.S.A, Lupin Europe GmbH - Germany, Lupin Biologics Limited - India, Lupin Oncology Inc. - U.S.A, Lupin Digital Health Limited - India, Avenue Coral Springs LLC - U.S.A., Southern Cross Pharma Pty Ltd - Australia, Lupin Life Sciences Limited - India (w.e.f. 17.07.2023), Lupin Manufacturing Solutions Limited - India (w.e.f. 24.07.2023), Medisol S.A.S. - France (w.e.f. September 01, 2023), Lymed S.A.S. - France (w.e.f. September 01, 2023 till July 08, 2024), Lupin Lanka (Private) Ltd. - Sri Lanka (w.e.f. 05.08.2024), Lupin NZ Ltd. - New Zealand (w.e.f. 05.08.2024) and a Trust, Lupin Foundation - India and a joint venture, YL Biologics Limited - Japan. 3. The Consolidated Financial Statements are prepared in accordance with Ind AS 110 Consolidated Financial Statements and Ind AS 28 Investments in Associates and Joint Ventures . 4. During the quarter ended 31.12.2024, 91,230 (year-to-date 555,634) equity shares of Rs. 2/- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans, resulting in an increase in the paid-up share capital by Rs. 0.2 mn (year-to-date Rs. 1.1 mn) and securities premium account by Rs. 108.3 mn (year-to-date Rs. 748.3 mn). 5. During the quarter and nine months ended 31.12.2024, the Group has made a provision of Rs. 856.1 mn (USD 10 mn) [quarter ended 30.09.2024: Rs. 585.1 mn (USD 7 mn)] and Rs. 1,441.2 mn (USD 17 mn) respectively towards ongoing disputes. 6. During the nine months ended 31.12.2023 and year ended March 31, 2024, Sales / Income from operations includes milestone income of Rs. 2,052.5 mn (USD 25.0 mn) from AbbVie for successful achievement of key milestone for its Phase 1 clinical stage MALT1 inhibitor program. 7. During the nine months ended 31.12.2024, Lupin Limited and its subsidiary, agreed to settle the dispute for an amount of USD 9.0 mn (Rs. 750.5 mn) in connection with the drug Glumetza® without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation. 8. During the year ended 31.03.2024, the Group had recognised an impairment charge of Rs. 2,012.5 mn related to intangibles assets (including discontinued ANDAs) and certain tangible assets. Multi segment 2024-04-01 2024-12-31 Unaudited Consolidated 170407700000.00 1388700000.00 171796400000.00 33479500000.00 20669300000.00 -2588300000.00 29629500000.00 2057700000.00 7760800000.00 49596300000.00 140604800000.00 31191600000.00 0.00 31191600000.00 7095800000.00 -1143000000.00 5952800000.00 0.00 25238800000.00 0.00 0.00 0.00 0.00 25238800000.00 -1145000000.00 24093800000.00 25091000000.00 147800000.00 23953300000.00 140500000.00 912500000.00 2 55.02 54.85 0.00 0.00 55.02 54.85 0.00 0.00 0.00 Net (gain)/ loss on foreign currency transactions 99500000.00 Other Expenses 16959200000.00 Net (gain)/ loss on foreign currency transactions 232600000.00 Other Expenses 49363700000.00 Others 262900000.00 Pharmaceuticals 57420400000.00 Others 739000000.00 Pharmaceuticals 169682000000.00 57683300000.00 170421000000.00 6200000.00 13300000.00 57677100000.00 170407700000.00 Others -372000000.00 Pharmaceuticals 11084700000.00 Others 1094500000.00 Pharmaceuticals 32286100000.00 10712700000.00 33380600000.00 10712700000.00 33380600000.00 Others 0.00 Pharmaceuticals 0.00 0.00 Others 0.00 Pharmaceuticals 0.00 0.00 Items that will not be reclassified subsequently to profit or loss 160000000.00 Items that will not be reclassified subsequently to profit or loss -55600000.00 160000000.00 -55600000.00 60100000.00 -15300000.00 Items that will be reclassified subsequently to profit or loss -1295200000.00 Items that will be reclassified subsequently to profit or loss -1009200000.00 -1295200000.00 -1009200000.00 0.00 95500000.00